Invention Grant
- Patent Title: Multispecific antibodies against IL-5 and IL-4R
-
Application No.: US16966237Application Date: 2019-02-15
-
Publication No.: US12030949B2Publication Date: 2024-07-09
- Inventor: Christophe Blanchetot , Marie Godar , Bart Lambrecht
- Applicant: argenx BV
- Applicant Address: BE Ghent
- Assignee: argenx BV
- Current Assignee: argenx BV
- Current Assignee Address: BE Ghent
- Agency: Dechert LLP
- Agent Andrew T. Wilkins; Kayla L. Metzger
- Priority: GB 02487 2018.02.15
- International Application: PCT/EP2019/053890 2019.02.15
- International Announcement: WO2019/158728A 2019.08.22
- Date entered country: 2020-07-30
- Main IPC: C07K16/18
- IPC: C07K16/18 ; C07K16/24 ; C07K16/28
Abstract:
The present invention relates to combination therapies and to their use in the treatment of chronic airway disease, particularly use in the treatment of asthma. The combination therapies comprise (i) an antagonist of IL-5:IL-5R and (ii) an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R. The present invention also provides bispecific antibodies comprising an antigen binding domain that binds to IL-4Rα and an antigen binding domain that binds to IL-5. The bispecific antibodies may be used for the treatment of chronic airway disease, particularly asthma.
Public/Granted literature
- US2200607A Method for making pure hydrogen Public/Granted day:1940-05-14
Information query
